@article {4834,
	title = {Estimating R\&D Returns In Health Care Industry},
	journal = {Central European Management Journal},
	volume = {26},
	year = {2018},
	month = {2018},
	pages = {34-46},
	abstract = {Purpose: This paper provides an empirical evaluation of R\&D returns for a series of global companies who lead in innovation within the health care industry.

Methodology: The estimation procedure bases on two specifications: the parametric production function setting, and finite distributed lag model (FDL).

Findings: Using the most recent data on R\&D investment by health care equipment and services along pharmaceuticals and biotechnology companies, we confirm the positive albeit mitigated impact of R\&D efforts on performance indicators (levels of sales). Moreover, we comment on the current phenomena observed in health care industry and offer a policy view for ongoing and future challenges in the sector.

Added value: Since there is a dearth of recent empirical evidence on R\&D returns in the broad health industry, this paper offers the evaluation of economic incentives for companies to invest in R\&D. These incentives embrace the induced increase in sales and profits levels. The authors participate in a public debate concerning the optimal levels of R\&D rewards required to sustain the innovation within the sector.},
	issn = {2658-0845 },
	doi = {10.7206/jmba.ce.2450-7814.227},
	url = {https://mbace.eu/resources/html/article/details?id=175131},
	author = {Karpa, Waldemar and Nowakowski, Jakub}
}
